Fig. 7. MRT68921 is efficacious in a metastatic syngeneic 4T1 murine breast cancer model.
a 4T1 cells (2 × 105) were harvested and injected intravenously into BALB/c mice. The treatment started on the third day after injection. The mice were intravenously injected with DMSO or MRT68921 (20 mg/kg/d) every day until the seventh treatment. (n = 7 per group). b Remaining mice were killed 24 days after treatment. Lungs from the vehicle- and MRT68921-treated groups demonstrated substantial differences in tumor burden. c H&E staining images of lungs. MRT68921 treatment significantly decreased the number of metastatic nodules, suggesting a lower tumor burden. d Survival curves and tumor burden of the 4T1 mice after treatment. Mice after MRT68921 treatment showed complete tumor regression and 71.4% survival over 24 days. e H&E staining of major organs (heart, liver, spleen, and kidney) after treatment with vehicle or MRT68921. No significant injuries were observed in either group.